• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS Expands Adult Stem Cell Organoid License to All Organs

Leiden, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.

“This is a crucial addition to our Organ-on-a-Chip disease models,” says Jos Joore, co-CEO of MIMETAS. “We typically combine HUB Organoids® with MIMETAS’ OrganoPlate® technology, adding connective tissues, vasculature, and immune cells. Thus, we create the most advanced organ mimics currently available. These miniature organs are used to develop therapies against incurable diseases, such as inflammatory bowel disease and liver fibrosis. With this expanded license, we will be able to broaden our use of adult stem cell-derived organoids to even more indications.”

HUB manages a world-leading patent portfolio for adult stem cell-derived organoid technology, originally developed in the lab of Professor Hans Clevers. Chief Business Officer of HUB Bahar Ramezanpour confirms, “We are delighted to expand our excellent collaboration with Mimetas. This ensures maximum utilization of two great technologies for the benefit of patients. In addition, Mimetas will now be able to expand its offering to other organs such as lung, kidney, and pancreas.”

Since its foundation in 2013, MIMETAS has collaborated extensively with the group of Professor Hans Clevers. This collaboration has resulted in a range of publications, including on the integration of kidney organoids1, 2 in the MIMETAS OrganoPlate and vascularization of liver organoids3. Clevers’ technology utilizes the regenerative capacity of patient-derived adult stem cells to reproduce organ functionality in the laboratory. A key difference between Clevers’ technology and embryonic and induced pluripotent stem cells is that the properties of the donor, including specific disease aspects, are maintained when cultured outside of the human body.


References
1Schutgens et al., 2019 Nature Biotechnology
2Gijssen et al., 2021 Nature Protocols
3Bonanini et al., 2022 in press



Read the original press release Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all